3-Fucosyllactose Prevents Nonalcoholic Fatty Liver Disease by Modulating the Gut Microbiota-Derived Pantothenate in Mice DOI
Bei Liu, Ningning He, Hui Li

и другие.

Journal of Agricultural and Food Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

Nonalcoholic fatty liver disease (NAFLD) is a growing global health threat. Human milk oligosaccharides (HMOs) exhibit prebiotic properties that may alleviate NAFLD progression. Herein, our study demonstrates 3-fucosyllactose (3-FL), distinctive and crucial HMO, significantly attenuates body weight gain, enhances hepatic lipid metabolism, reduces inflammation in high-fat diet (HFD)-induced mouse model. These findings suggest its potential as dietary supplement for preventing alleviating Subsequently, fecal metagenomic nontargeted metabolomics analyses revealed 3-FL treatment alleviated HFD-induced gut microbiota dysbiosis, with specific enhancement of the pantothenate (vitamin B5) metabolic pathways. Our targeted metabolite analysis further significant increase both concentrations, which contributed to coenzyme A (CoA)-mediated metabolism pathway. Furthermore, subsequent population cohort correlation between serum levels progression NAFLD, thereby reinforcing candidacy noninvasive diagnostic biomarker. show acts an effective symptoms, part by enhancing microbiota-mediated pantothenate/CoA

Язык: Английский

The neonatal gut microbiome in health and disease DOI Creative Commons
Geoffrey A. Preidis

Gut Microbes, Год журнала: 2025, Номер 17(1)

Опубликована: Янв. 27, 2025

Язык: Английский

Процитировано

0
3-Fucosyllactose Prevents Nonalcoholic Fatty Liver Disease by Modulating the Gut Microbiota-Derived Pantothenate in Mice DOI
Bei Liu, Ningning He, Hui Li

и другие.

Journal of Agricultural and Food Chemistry, Год журнала: 2025, Номер unknown

Опубликована: Апрель 15, 2025

Nonalcoholic fatty liver disease (NAFLD) is a growing global health threat. Human milk oligosaccharides (HMOs) exhibit prebiotic properties that may alleviate NAFLD progression. Herein, our study demonstrates 3-fucosyllactose (3-FL), distinctive and crucial HMO, significantly attenuates body weight gain, enhances hepatic lipid metabolism, reduces inflammation in high-fat diet (HFD)-induced mouse model. These findings suggest its potential as dietary supplement for preventing alleviating Subsequently, fecal metagenomic nontargeted metabolomics analyses revealed 3-FL treatment alleviated HFD-induced gut microbiota dysbiosis, with specific enhancement of the pantothenate (vitamin B5) metabolic pathways. Our targeted metabolite analysis further significant increase both concentrations, which contributed to coenzyme A (CoA)-mediated metabolism pathway. Furthermore, subsequent population cohort correlation between serum levels progression NAFLD, thereby reinforcing candidacy noninvasive diagnostic biomarker. show acts an effective symptoms, part by enhancing microbiota-mediated pantothenate/CoA

Язык: Английский

Процитировано

0